PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
G01N 33/574, 33/569, C12Q 1/68

A1

(11) International Publication Number: **WO 00/70348**

(43) International Publication Date: 23 November 2000 (23.11.00)

(21) International Application Number: PCT/AU00/00441

(22) International Filing Date: 15 May 2000 (15.05.00)

(30) Priority Data:
PQ 0377 14 May 1999 (14.05.99) AU

(71) Applicant *(for all designated States except US)*: VRI BIOMEDICAL LIMITED [AU/AU]; Level 29, Chifley Square, Sydney, NSW 2000 (AU).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: CLANCY, Robert, Llewellyn [AU/AU]; 11 High Street, Newcastle, NSW 2300 (AU). PANG, Gerald [AU/AU]; 4/25 Billyard Avenue, Elizabeth Bay, NSW 2011 (AU).

(74) Agent: BALDWIN SHELSTON WATERS; 60 Margaret Street, Sydney, NSW 2000 (AU).

(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: METHODS FOR PREDICTING AND/OR DIAGNOSING THE RISK OF GASTRIC CANCER

(57) Abstract

The present invention relates to methods of predicting the risk of developing cancer and in particular to a method for diagnosing, and/or predicting the risk of developing gastric cancer in a subject infected with *Helicobacter*.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

METHODS FOR PREDICTING AND/OR DIAGNOSING THE RISK OF GASTRIC CANCER

TECHNICAL FIELD

The present invention relates to methods of predicting the risk of developing cancer and in particular to a method for diagnosing, and/or predicting the risk of developing, gastric cancer in a subject infected with *Helicobacter pylori*.

BACKGROUND

Helicobacter pylori infection is now recognised as an essential pre-requisite for the development of gastric cancer. About 30% of the population become infected with this bacterium and commonly present with chronic gastritis. This may be complicated by gastric or duodenal ulceration, or may present as non-ulcer dyspepsia. A sizeable number of carriers are asymptomatic. However, in a small number of patients with *H. pylori,* their condition evolves through stages (including epithelial cell metaplasia and dysplasia) into neoplasia. The factors responsible for this evolution are complicated, but involve geographical, environmental and genetic parameters. Of particular importance is the host response. Current evidence supports the theory that a particular T cell response known as Th1 (characterised by production of γinterferon (γIFN) but not interleukin-4 (IL-4)) as promoting mucosal damage. Alternatively, a Th0 response can occur which includes balanced production of these cytokines (γIFN and IL-4) and which favours protection from mucosal damage. Patterns of mucosal cytokine response associated with neoplastic transformation and tumour progression have not been described.

Current Management Practice of *H. pylori* Infection

H. pylori is an essential component of the chain of events leading to chronic gastritis and peptic ulceration. Eradication of infection with antibiotics induces an 80-

90% cure rate of peptic ulceration. A widely accepted treatment paradigm is based on detection of infection using antibody assays, followed by combination antibiotic therapy without prior endoscopic diagnosis. Endoscopy, before eradication therapy is generally accepted when 'danger' symptoms (eg, severe pain, bleeding) occur, or a significant risk of gastric cancer is present. However, endoscopy is a procedure which is associated with its own risks and is to be avoided if possible.

At present, no non-invasive test exists which would allow for prediction or diagnosis of gastric cancer in patients which *Helicobacter* infection. Such a test would be particularly valuable for patients who present with relatively mild symptoms but who are identified as being in a "high risk" category and who would otherwise automatically be required to undergo an endoscopy - with its attendant risks. Even in patients who present with "danger symptoms" and who may still require an endoscopy, such a non-invasive test could be used as a complementary tool in diagnosis. This change in practice could have a significant impact on health economics.

It is an object of the present invention to overcome or ameliorate at least one of the disadvantages of the prior art, or to provide a useful alternative.

SUMMARY OF THE INVENTION

It has surprisingly been found that mucosal IgG2 anti-*H. pylori* antibody and γIFN levels are decreased and IL-4 levels are elevated in patients having *Helicobacter* infection when gastric cancer or precancer lesions (metaplasia and dysplasia) are present. These changes are also reflected in the blood of such patients. However, the changes are not seen in other disorders in which *Helicobacter pylori* is colonising the gastric mucosa.

According to a first aspect, the present invention provides a method of diagnosing and/or determining the risk of developing gastric cancer in a subject with a *Helicobacter* infection, including:

a) determination of IgG2 anti-*H. pylori* antibody level in the subject;

b) comparison of the IgG2 anti-*H. pylori* antibody level with a predetermined control IgG2 anti-*H. pylori* antibody level, wherein a reduction in the level of IgG2 anti-*H. pylori* antibody in the subject compared to the control indicates the presence and/or increased risk of developing gastric cancer.

According to a second aspect, the present invention provides a method of diagnosing and/or determining the risk of developing gastric cancer in a subject with a *Helicobacter* infection, including:

a) determination of γIFN level in the subject;

b) comparison of the γIFN level with a predetermined control γIFN level, wherein a reduction in the level of γIFN in the subject compared to the control indicates the presence and/or increased risk of developing gastric cancer.

According to a third aspect, the present invention provides a method of diagnosing and/or determining the risk of developing gastric cancer in a subject with a *Helicobacter* infection, including:

a) determination of IL-4 level in the subject;

b) comparison of the IL-4 level with a predetermined control IL-4 level, wherein an elevation in the level of IL-4 in the subject compared to the control indicates the presence and/or increased risk of developing gastric cancer.

According to a fourth aspect, the present invention provides a method of diagnosing and/or determining the risk of developing gastric cancer in a subject with a *Helicobacter* infection, including a combination of a method according to the first aspect and/or a method according to claim second aspect and/or a method according to the third aspect.

According to a fifth aspect, the present invention provides a method of diagnosing and/or determining the risk of developing gastric cancer in a subject with a *Helicobacter* infection, including a combination of a method according to the second aspect and a method according to the third aspect.

Preferably, the *Helicobacter* infection is a *Helicobacter pylori* infection.

Preferably, the IgG2 anti-*H. pylori* antibody, γIFN and/or IL-4 levels are determined by detection in a sample of biological fluid such as for example blood, saliva, gastric fluid and the like.

Preferably, the measurement of IgG2 anti-*H. pylori* antibody, γINF and/or IL-4 either simultaneously provides, or can be performed simultaneously with, a method which provides an indication of *H. pylori* status.

Preferably, the IgG2 anti-*H. pylori* antibody and/or γIFN and/or IL-4 are detected by a near-subject assay. The assay may, however, also be a laboratory-based test. Preferably, the assay is an antibody assay although it will be understood that other known methods of measurement can also be effectively used. Most preferably, the assay is an ELISA .

According to a sixth aspect, the present invention provides a method of predicting the risk of, and/or diagnosing, gastric cancer in a subject having a *Helicobacter* infection by

a) determining the frequency of IgG2 anti-*H.pylori* antibody- and/or γIFN- and/or IL-4-producing cells in the subject's blood; and

b) comparison of the frequency of IgG2 anti-*H.pylori* antibody- and/or γIFN- and/or IL-4-producing cells in the subject's blood with a predetermined control level, wherein a reduction in the level of IgG2 anti-*H.pylori* antibody- and/or γIFN-producing cells and/or an elevation in IL-4-producing cells in the subject's blood indicates the presence and/or increased risk of developing gastric cancer.

It will be clear to the skilled addressee that the blood may be purified to provide an enriched white blood cell population and the white blood cell population may be further fractionated to obtain specific cell populations.

Preferably, the IgG2 anti-*H.pylori* antibody- and/or γIFN- and/or IL-4-producing cells are stimulated with *H. pylori* antigen prior to measurement of IgG2 anti-*H.pylori* antibody and/or γIFN and/or IL-4.

According to a seventh aspect, the present invention provides a method of predicting the risk of, and/or diagnosing, gastric cancer in a subject having a *Helicobacter* infection by

a) determining the frequency of IgG2 anti-*H.pylori* antibody and/or γIFN and/or IL-4-producing cells in the subject's gastric mucosa; and

b) comparison of the frequency of IgG2 anti-*H.pylori* antibody and/or γIFN and/or IL-4-producing cells in the subject's gastric mucosa with a predetermined control level,

wherein a reduction in the level of IgG2 anti-*H.pylori* antibody- and/or γIFN-producing cells and/or an elevation in IL-4-producing cells in the subject's gastric mucosa indicates the presence and/or increased risk of developing gastric cancer.

Preferably, the cells are derived from a biopsy sample.

Preferably, the IgG2 anti-*H.pylori* antibody- and/or γIFN- and/or IL-4-producing cells are detected by flow cytometry.

Control levels of IgG2 anti-*H. pylori* antibody, IL-4 and/or γIFN can be established in samples of biological fluids obtained from normal individuals, ie. those not having an established *H. pylori* infection, or they can be established in samples from subjects with *H. pylori* infection who have uncomplicated chronic gastritis or asymptomatic infection or the like. In certain cases, in which subjects are followed prospectively, control levels may be internal levels, i.e. the subject's own control levels.

The method of the present invention can also be used to diagnose and/or determine the risk of developing pre-cancer lesions such as metaplasia or dysplasia by way of measurement of IgG2 anti-*H. pylori* antibody, γIFN and/or IL-4.

It will be clear to the skilled addressee that ratios of IgG2 anti-*H. pylori* antibody, γIFN or IL-4 to other parameters such as, for example total IgG anti-*H. pylori* antibody may be useful as a predictor of, or in the diagnosis of, gastric precancerous or cancerous conditions, including situations in whch dysplasia and metaplasia are present. Refinement of the prediction and/or diagnosis of precancerous or cancerous conditions may require that specific ratios be utilised, such as the ratio of IL-4:γIFN, IgG2:total IgG or IgG2:IgG1. However, other ratios may also be useful.

In the context of the present invention, the abbreviations "γIFN" and "IFNγ" have been used interchangably in the specification to refer to the cytokine γ interferon.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1. Detection of IL-4 in supernatants of gastric mucosal cultures from subjects with gastric cancer or pre-cancer lesions (metaplasia or dysplasia). In uncomplicated *H. pylori* infection (or in benign peptic ulcers) a Th1 pattern of cytokine (eg, γINF) is found.

Figure 2. This figure illustrates a high level of correlation between secretion of IL-4 from mucosal biopsies, and *H. pylori* antigen stimulated blood T cells. IL-4 was not secreted from antigen stimulated T cells in untreated subjects with uncomplicated chronic gastritis and *H. pylori* infection.

Figure 3. Cytokine (IL-8, IL-4 and γIFN) production in the gastric mucosa of subjects infected with *H. pylori*..

Figure 4. IgG1 and IgG2 anti-*H. pylori* antibody levels in serum of *H. pylori*-infected subjects having various gastrointestinal disorders.

Figure 5. IgG1 and IgG2 anti-*H. pylori* antibody levels in serum of *H. pylori*-infected subjects having various gastrointestinal disorders.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The invention will now be described in more detail with reference to non-limiting examples.

It was previously known that total IgG anti-*H. pylori* antibody levels in blood and gastric mucosa can be used as an indicator of *H. pylori* status. In the following examples, therefore, it will be understood that, while IgG anti-*H. pylori* can be utilised as a general indicator of *H. pylori* status, the invention also relates to the measurement of the IgG2 subclass which can be used as a predictor of, or in the diagnosis of, gastric cancer.

Techniques for measurement of cytokines and antibodies in human samples are well-known in the art and protocols and reagents are readily available. Examples of some of the techniques used are indicated below as an illustration of how some measurements may be performed.

Unless indicated otherwise, standard techniques which can be ascertained from standard texts and laboratory manuals may be employed.

Example 1 Determination of cytokine and antibody levels in a blood sample

The standard assay involves coating microwells of a 96-well microtitre plate with monclonal anti-IL-4 (MoAb). After removal of antibody and washing with PBS/Tween 20, 100 uL of whole blood is added to each well containing an equal volume of AIM-V medium. After incubation for 24 hrs at 37°C, the plasma supernatant is removed for measurement of γIFN by ELISA (Figure 1). The amount of IL-4 captured by IL-4 MoAb in each well is measured by ELISA (Figures 1 and 2). IgG1 and IgG2 subclass anti-*H. pylori* levels or IgG2/IgG ratios in serum from clotted blood or plasma supernatant (above) are measured by ELISA (Figures 4, 5). All samples are stored at -80°C until assay.

Assay system for measurement of IL-4 alone or IL-4 and anti-*H. pylori* IgG antibodies at the same time.

Wells of a 96-well flat-bottomed microtitre plate are coated with 2 μg/mL of monoclonal anti-IL-4 capture antibody in sodium bicarbonate buffer pH 8.5. After removal of antibody solution, an equal volume of freshly collected whole blood is added to each well. After incubation for 24 hrs at 37°C, the plasma supernatant as removed and IL-4 bound is detected by reaction with biotinylated anti-IL-4 antibody and strepavidin-peroxidase conjugate. The amount of IL-4 is measured by colour development read in a plate reader with the appropriate standards.

On the same plate, IgG anti-*H. pylori* antibody is detected by adding the plasma supernatant to wells coated with 4 ug/mL of *H. pylori* antigens using an ELISA assay. The results are shown in Table 1.

Table 1 IL-4 production and anti-*H. pylori* IgG antibody in whole blood

Subject	IL-4 production (pg/mL)	*H. pylori* IgG (ELISA Index)
S1	42.77	0.696
S2	9.4	1.61
S3	13.49	1.86
S4	108.25	0.95
S5	9.4	1.83
S6	18.1	0.67
S7	9.4	4.32
S8	19.41	3.22
S9	56.64	3.48
S10	15.1	3.42
S11	9.4	0.12

Example 2 Frequency of IL-4 and γIFN producing cells in gastric mucosa

Gastric T cells are isolated from biopsy tissues obtained at endoscopy. The tissues is rinsed in 1mM dithiothreitol and 1mM EDTA to remove epithelial cells and intraepithelial cells before extraction of lamina propria T cells in serum-free AIM-V medium containing 40 U collagenase (Worthington Biochemical) for 2-3 hrs. The viability of the mononuclear cells after removal of undigested materials was >90% by trypan blue exclusion. Isolated gastric mononuclear cells from individual biopsies are usually too low (about 0.503×10^5 cells per biopsy) for antigen-mediated re-stimulation in bulk cultures. Therefore, IL-4 and γIFN producer frequencies in each cell isolate are determined by intracellular staining and then analysed on the FACS Vantage using 3-colour flow cytometry. Isolated gastric cells were activated with PMA and ionomycin and PMA, stained with PerCP-CD3 monoclonal antibody (Becton Dickinson) and then processed for intracellular staining with FITC-γIFN and PE-IL-4 monoclonal antibody as described above.

Unless indicated otherwise above, standard techniques which can be ascertained from standard laboratory texts were used.

Table 2 provides an example of the predictions/diagnoses which can be made on the basis of the above tests.

Table 2

IgG anti-*H. pylori* antibody +ve IL-4 -ve	low cancer risk endoscopy not indicated on age indications alone
IgG anti-*H. pylori* antibody +ve IL-4 +ve	high cancer risk needs endoscopy as early intervention
IgG anti-*H. pylori* antibody -ve IL-4 -ve	no evidence of *H. pylori* infection

Example 3 Frequency of IL-4 and γIFN producing cells in peripheral blood

Intracellular cytokine staining and detection by flow cytometry is used to estimate cytokine-producer frequencies of IL-4 and γIFN amongst different subjects. This allows comparison of results obtained from gastric biopsy tissue where analysis by limiting dilution culture following antigen re-stimulation is not possible due to low numbers of cells isolated per biopsy. Peripheral blood mononuclear cells or whole blood is activated with phorbol myristate acetate (PMA, 50 ng/mL) and 1 μM ionomycin for 4-5 hrs in the presence of 2 μM monensin, fixed, permeabilised and stained with FITC/PE labelled γIFN/IL-4 (Bectin-Dickinson). γIFN and IL-4 frequencies are then analysed by flow cytometry with matched isotype IgG control and gated for lymphocytes.

The frequencies of IL-4 and γIFN producing cells in peripheral blood from subjects with or without *H. pylori* infection are shown in Tables 3 and 4. The ratios of γIFN:IL-4 producing cells were higher in subjects infected with *H. pylori* than in non-infected subjects.

Limiting dilution analysis was used to determine quantitative estimates of the frequency of circulating IL-4 and γIFN-secreting cells in blood using short-term cultures stimulated with Hp recombinant antigen (citrate synthase of Hp 0310). A non-protective recombinant antigen Hp-0162 was used as a negative control. Cells are seeded in V-bottomed 96-well microplate using twofold dilution from 10^5 to 2.5 x 10^3 cells at 24 replicates per cell concentration. Cultures were stimulated with a predetermined concentration of citrate synthase or Hp 0310 antigen in the presence of rIL-2 (5 U/mL) for 3 days. Controls contained no responder cells or responder cells in medium and rIL-2 without antigen. As IL-4 is unstable an antibody capture method is used with bound

IL-4 measured by ELISA using a matched antibody pair (Endogen/CSL). γIFN production is measured in the supernatant by standard methods. Frequencies of peripheral blood mononuclear cells producing IL-4 and γIFN are calculated by maximum likelihood method using appropriately validated computer software.

Table 3 Cytokine producing cells in *H. pylori* antibody POSITIVE subjects

Subjects	γIFN(%)	IL-4 (%)	γIFN:IL-4 ratio
S1	18.3	2.5	7.3
S2	25.4	3.3	7.6
S3	26.0	11.5	2.3
S4	9.6	2.6	3.7
S5	14.8	5.6	2.6
Mean ± SE			4.7 ± 1.15*

Table 4 Cytokine producing cells in *H. pylori* antibody NEGATIVE subjects

Subjects	γIFN (%)	IL-4 (%)	γIFN:IL-4 ratio
S6	24.8	28.3	0.9
S7	8.9	3.0	3.0
S8	8.1	2.6	3.1
S9	29.9	29.1	1.0
S10	25.9	17.2	1.5
Mean ± SE			1.9 ± 0.48*

* p=0.054

Figures 1 to 5 provide results obtained utilising the tests exemplified below in studies of subjects having various gastrointestinal conditions i.e. reflux, gastritis, duodenal ulcer, gastric ulcer and gastric cancer. The Figures are self-explanatory and show that levels of

IgG2, γIFN and IL-4 can be used as predictors of, and in the diagnosis of, gastric cancer in patients having *H. pylori* infection.

Although the invention has been described with reference to specific examples, it will be appreciated by those skilled in the art that the invention may be embodied in many other forms without departing from the spirit or intent of the inventive concept.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A method of diagnosing and/or determining the risk of developing gastric cancer in a subject with a *Helicobacter* infection, including:

a) determination of IgG2 anti-*H. pylori* antibody level in the subject;

b) comparison of the IgG2 anti-*H. pylori* antibody level with a predetermined control IgG2 anti-*H. pylori* antibody level, wherein a reduction in the level of IgG2 anti-*H. pylori* antibody in the subject compared to the control indicates the presence and/or increased risk of developing gastric cancer.

2. A method of diagnosing and/or determining the risk of developing gastric cancer in a subject with a *Helicobacter* infection, including:

a) determination of γIFN level in the subject;

b) comparison of the γIFN level with a predetermined control γIFN level, wherein a reduction in the level of γIFN in the subject compared to the control indicates the presence and/or increased risk of developing gastric cancer.

3. A method of diagnosing and/or determining the risk of developing gastric cancer in a subject with a *Helicobacter* infection, including:

a) determination of IL-4 level in the subject;

b) comparison of the IL-4 level with a predetermined control IL-4 level, wherein an elevation in the level of IL-4 in the subject compared to the control indicates the presence and/or increased risk of developing gastric cancer.

4. A method of diagnosing and/or determining the risk of developing gastric cancer in a subject with a *Helicobacter* infection, including a combination of a method

according to claim 1 and/or a method according to claim 2 and/or a method according to claim 3.

5. A method of diagnosing and/or determining the risk of developing gastric cancer in a subject with a *Helicobacter* infection, including a combination of a method according to claim 2 and a method according to claim 3.

6. A method according to any one of claims 1 to 6 wherein the *Helicobacter* infection is a *Helicobacter pylori* infection.

7. A method according to any one of claims 1 to 7 wherein the IgG2 anti-*H. pylori* antibody, γIFN and/or IL-4 levels are determined by detection of the levels in a sample of biological fluid.

8. A method according to claim 7 wherein the biological fluid is blood.

9. A method according to claim 7 wherein the biological fluid is saliva.

10. A method according to claim 7 wherein the biological fluid is gastric fluid.

11. A method according to any one of claims 1 to 10 wherein the measurement of IgG2 anti-*H. pylori* antibody, γINF and/or IL-4 either simultaneously provides, or can be performed simultaneously with, a method which provides an indication of *H. pylori* status.

12. A method according to any one of claims 1 to 11 wherein the IgG2 anti-*H. pylori* antibody, γIFN and/or IL-4 are detected by a near-subject assay.

13. A method according to any one of claims 1 to 11 wherein the assay is a laboratory-based test.

14. A method according to claim 12 or claim 13 wherein the assay is an antibody assay.

15. A method according to claim 14 wherein the antibody assay is an ELISA.

16. A method of predicting the risk of, and/or diagnosing, gastric cancer in a subject having a *Helicobacter* infection by

a) determining the frequency of IgG2 anti-*H.pylori* antibody- and/or γIFN- and/or IL-4-producing cells in the subject's blood; and

b) comparison of the frequency of IgG2 anti-*H.pylori* antibody- and/or γIFN- and/or IL-4-producing cells in the subject's blood with a predetermined control level, wherein a reduction in the level of IgG2 anti-*H.pylori* antibody- and/or γIFN-producing cells and/or an elevation in IL-4-producing cells in the subject's blood indicates the presence and/or increased risk of developing gastric cancer.

17. A method according to claim 16 wherein the blood is purified to provide an enriched white blood cell population.

18. A method according to claim 17 wherein the white blood cell population is further fractionated to obtain specific cell populations.

19. A method according to any one of claims 16 to 18 wherein the IgG2 anti-*H.pylori* antibody- and/or γIFN- and/or IL-4-producing cells are stimulated with *H. pylori* antigen prior to measurement of IgG2 anti-*H.pylori* antibody and/or γIFN and/or IL-4.

20. A method of predicting the risk of, and/or diagnosing, gastric cancer in a subject having a *Helicobacter* infection by

a) determining the frequency of IgG2 anti-*H.pylori* antibody and/or γIFN and/or IL-4-producing cells in the subject's gastric mucosa; and

b) comparison of the frequency of IgG2 anti-*H.pylori* antibody and/or γIFN and/or IL-4-producing cells in the subject's gastric mucosa with a predetermined control level,

wherein a reduction in the level of IgG2 anti-*H.pylori* antibody- and/or γIFN-producing cells and/or an elevation in IL-4-producing cells in the subject's gastric mucosa indicates the presence and/or increased risk of developing gastric cancer.

21. A method according to claim 20 wherein the cells are derived from a biopsy sample.

22. A method according to claim 20 or claim 21 wherein of IgG2 anti-*H.pylori* antibody and/or γIFN and/or IL-4-producing cells are detected by flow cytometry.

FIGURE 1


120
100
80
60
40
20
0
pg/mL
IL-4
IFNγ
Gastritis
Dysplasia
Carcinoma

FIGURE 2


Unstimulated
p < 0.0040
r2 = 0.621
Whole Blood IL-4 (pg/mL)
Gastric mucosal IL-4 (pg/mL)
0
20
40
60
80


H pylori (1 µg/mL)
p < 0.0002
r2 = 0.804
Whole Blood IL-4 (pg/mL)
Gastric mucosal IL-4 (pg/mL)
0
20
40
60
80
100
120

FIGURE 3


Mucosal IL-8
IL-8 (ng/mL)
25.00
20.00
15.00
10.00
5.00
0.00
H.pylori -/Gastritis n=11
H.pylori +/Gastritis n=12
Dysplasia/Eradicated n=8
H. pylori -/Cancer n=9
H. pylori +/Cancer n=9
Mucosal IL-4
IL-4 (pg/mL)
80.00
60.00
40.00
20.00
0.00
H.pylori -/Gastritis n=11
H.pylori +/Gastritis n=12
Dysplasia/Eradicated n=11
H. pylori -/Cancer n=9
H. pylori +/Cancer n=9
Mucosal IFN-γ
IFN-γ (pg/mL)
125.00
100.00
75.00
50.00
25.00
0.00
H.pylori -/Gastritis n=11
H.pylori +/Gastritis n=12
Dysplasia/Eradicated n=11
H. pylori -/Cancer n=9
H. pylori +/Cancer n=9

FIGURE 4


Serum IgG subclass in H. pylori infection
ELISA Units (OD 450 nm)
1500
1000
500
0
IgG1
IgG2
Esophagus reflux
Chronic gastritis
Gastric cancer
Dysplasia/eradicated
n = 6
n = 20
n = 7
n = 9

FIGURE 5


1500
1000
500
0
ELISA UNITS (OD 450 nm)
Serum IgG1
Serum IgG2
*
*
*
Reflux
Chronic gastritis
Duodenal ulcer
Gastric ulcer
Gastric cancer
n=6
n=16
n=13
n=8
n=9

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU00/00441

A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl. [7]: G01N 33/574, G01N 33/569, C12Q 1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC G01N, C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Derwent WPAT, JAPIO; STN MEDLINE CAPLUS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	Journal of Gastroenterology, vol. 31(4), 485-490; Ishihara, S. et al. (1996) Cytokine gene expression in the gastric mucosa: Its role in chronic gastritis. See the introduction, tables, figures and discussion in particular.	2-16, 19-21 1-22
X Y	Immunology Letters, vol. 48(1), 45-8; Fan, X. et al. (1995) Effect of IL-4 on peripheral blood lymphocyte proliferation: implication in immunopathogenesis of H.pylori infection. See the introduction and discussion in particular.	2-22 1-22
X Y	Infection and Immunity, vol.67 (1), 279-85; Sawai, N. et al. (1999) Role of Gamma Interferon in Helicobacter pylori-Induced Gastric Inflammatory Responses in a Mouse Model. See the abstract and the conclusion in particular.	2, 4-22 1-22

[X] Further documents are listed in the continuation of Box C [X] See patent family annex

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
23 June 2000	04 JUL 2000
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized officer **DAVID HENNESSY** Telephone No : (02) 6283 2255

INTERNATIONAL SEARCH REPORT	International application No. PCT/AU00/00441

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Italian Journal of Gastroenterology and Hepatology, vol. 31(5), 408-15; Zagari, R.M. et al. (1999) Review article: non-invasive methods for the diagnosis of Helicobacter pylori infection. See serology, references 7,8 in particular.	1-22
X Y	The Lancet, vol. 347, 269-270; Liston, R. et al. (1996) IgG ELISA antibodies and detection of Helicobacter pylori in elderly patients. See both letters.	1, 6-22 2-5
X Y	Journal of Clinical Pathology, vol. 49, 112-115; Osawa, H. et al. (1996) Inverse relation of serum Helicobacter pylori antibody titres and extent of intestinal metaplasia. See the whole article.	1,6-22 2-5
X Y	Gut, vol. 36, 341-5; Karttunen, R. et al. (1995) Interferon gamma and interleukin 4 secreting cells in the gastric antrum in Helicobacter pylori positive and negative gastritis. See pages 341 and 344 in particular.	2-22 1
T	Journal of Gastroenterology, vol. 34, 560-570; Itoh, T. et al. (1999) The vast majority of gastric T cells are polarized to produce T helper 1 type cytokines upon antigenic stimulation despite the absence of Helicobacter pylori infection.	1-22
A	WO 96/12965 A1 (Genelabs Diagnostics Pty Ltd) 02.05.96; see 'Background of the Invention', example 2 and claim 1 in particular.	1-22
Y	WO 98/24885 A1 (Sanitaria Scaligera S.P.A.) 11.06.98; See the examples in particular.	1-22

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/AU00/00441

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member	
WO	96/12965	AU	38143/95
WO	98/24885	IT	1289578

END OF ANNEX

专利名称(译)	预测和/或诊断胃癌风险的方法		
公开(公告)号	EP1183540A1	公开(公告)日	2002-03-06
申请号	EP2000924979	申请日	2000-05-15
[标]申请(专利权)人(译)	ONCO警报		
申请(专利权)人(译)	ONCO ALERT PTY LTD		
当前申请(专利权)人(译)	ONCO ALERT PTY LTD		
[标]发明人	CLANCY ROBERT LLEWELLYN PANG GERALD		
发明人	CLANCY, ROBERT, LLEWELLYN PANG, GERALD		
IPC分类号	G01N33/68 C12Q1/02 G01N33/50 G01N33/53 G01N33/569 G01N33/574 C12Q1/68		
CPC分类号	G01N33/6854 G01N33/5047 G01N33/57446 G01N2333/205 G01N2333/5406 G01N2333/57 G01N2469/20		
优先权	1999PQ0377 1999-05-14 AU		
其他公开文献	EP1183540A4		
外部链接	Espacenet		

摘要(译)

本发明涉及预测患癌症风险的方法，尤其涉及诊断和/或预测感染了螺杆菌的受试者中发生胃癌的风险的方法。